Source: Alzheimer's News Today. By: Iqra F. Mumal. Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. view more